11.19.14
AMRI’s Albuquerque, NM sterile injectable facility has resumed full manufacturing operations. The company has completed remediation following an environmental deviation in one manufacturing suite as a result of a weather related business interruption this past September.
AMRI's OsoBio facility, acquired in July 2014, provides cGMP manufacturing and sterile filling of parenteral drugs using specialized technologies, including lyophilization. OsoBio also supports commercial scale production of liquid-filled and lyophilized parenterals for both small molecule drug products, as well as biologics.
William S. Marth, AMRI's president and chief executive officer, said, "We are pleased to report that all suites at our OsoBio Albuquerque aseptic manufacturing facility are fully operational. I would like to acknowledge and thank our colleagues and vendors for their dedicated efforts in remediating the affected manufacturing suite as quickly as possible."
AMRI's OsoBio facility, acquired in July 2014, provides cGMP manufacturing and sterile filling of parenteral drugs using specialized technologies, including lyophilization. OsoBio also supports commercial scale production of liquid-filled and lyophilized parenterals for both small molecule drug products, as well as biologics.
William S. Marth, AMRI's president and chief executive officer, said, "We are pleased to report that all suites at our OsoBio Albuquerque aseptic manufacturing facility are fully operational. I would like to acknowledge and thank our colleagues and vendors for their dedicated efforts in remediating the affected manufacturing suite as quickly as possible."